The clinical management of patients with relapsed or refractory multiple myeloma is challenging and there is a paucity of tools to help clinicians make more informed decisions for the most suitable treatment options. We aimed to investigate the clinical utility of the International Myeloma Working Group (IMWG) frailty score in the setting of relapsed or refractory multiple myeloma, by examining its ability to capture different patient-reported health-related quality of life profiles.
Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study / Efficace, Fabio; Gaidano, Gianluca; Petrucci, Maria Teresa; Niscola, Pasquale; Cottone, Francesco; Codeluppi, Katia; Antonioli, Elisabetta; Tafuri, Agostino; Larocca, Alessandra; Potenza, Leonardo; Fozza, Claudio; Pastore, Domenico; Rigolin, Gian Matteo; Offidani, Massimo; Romano, Alessandra; Kyriakou, Charalampia; Cascavilla, Nicola; Gozzetti, Alessandro; Derudas, Daniele; Vignetti, Marco; Cavo, Michele. - In: THE LANCET. HEALTHY LONGEVITY. - ISSN 2666-7568. - 3:9(2022), pp. 628-635. [10.1016/S2666-7568(22)00172-6]
Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study
Fozza, Claudio;
2022-01-01
Abstract
The clinical management of patients with relapsed or refractory multiple myeloma is challenging and there is a paucity of tools to help clinicians make more informed decisions for the most suitable treatment options. We aimed to investigate the clinical utility of the International Myeloma Working Group (IMWG) frailty score in the setting of relapsed or refractory multiple myeloma, by examining its ability to capture different patient-reported health-related quality of life profiles.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
